Targets of complement-fixing antibodies in protective immunity against malaria in children

scientific article published in Nature Communications

Targets of complement-fixing antibodies in protective immunity against malaria in children is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2019NatCo..10..610R
P6179Dimensions Publication ID1111912077
P356DOI10.1038/S41467-019-08528-Z
P932PMC publication ID6363798
P698PubMed publication ID30723225

P50authorFreya FowkesQ42800053
Michelle J BoyleQ55174963
Danny W WilsonQ56476038
Ivo MuellerQ60043791
Takafumi TsuboiQ63860522
Linda ReilingQ118533572
P2093author name stringMichael T White
James G Beeson
Eizo Takashima
Peter M Siba
Jack S Richards
Gaoqian Feng
D Herbert Opi
Kristina E M Persson
Rupert Weaver
P2860cites workPhase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in BandiagaraQ37220681
The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malariaQ37239883
Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccinationQ37459461
The future for blood-stage vaccines against malariaQ37471465
The wheat germ cell-free protein synthesis system: a key tool for novel malaria vaccine candidate discoveryQ37632828
Malaria vaccines and human immune responsesQ38854831
Functional Antibodies and Protection against Blood-stage MalariaQ38933541
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal KenyaQ39362550
Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria.Q39417737
Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infectionQ44147641
Antibodies among men and children to placental-binding Plasmodium falciparum-infected erythrocytes that express var2csa.Q46337040
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsQ47576664
IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria.Q47830190
Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemiaQ47954510
Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malariaQ47957417
Gamma-globulin and acquired immunity to human malariaQ47957467
Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese viQ48000659
Immunization of malaria pre-exposed volunteers with PfSPZ Vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodiesQ50041449
Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria ExposureQ50062994
Acquired immunity to malariaQ24651173
Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malariaQ26772878
Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseasesQ26825548
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferaseQ27860571
Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult MaliansQ33302903
Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.Q33305467
Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparumQ33380204
Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adultsQ33380213
The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysisQ33526349
Evaluation of the antigenic diversity of placenta-binding Plasmodium falciparum variants and the antibody repertoire among pregnant womenQ33826049
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarrayQ33859633
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1Q33870167
Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assaysQ33939788
Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccineQ34011922
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trialQ34043843
Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug developmentQ34069682
Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humansQ34081745
High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malariaQ34171724
Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccinesQ34416904
The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria.Q34428497
Research priorities for the development and implementation of serological tools for malaria surveillanceQ34500035
Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodiesQ34680704
Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malariaQ34827195
Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malariaQ35213495
New antigens for a multicomponent blood-stage malaria vaccineQ35216634
A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigensQ36141540
Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodiesQ36227228
Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccineQ36304234
Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.Q36368911
Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?Q36391845
Vaccine candidate discovery for the next generation of malaria vaccines.Q36413834
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker developmentQ36984161
The risk of malarial infections and disease in Papua New Guinean children.Q37088901
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illnessQ37099503
Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children.Q52715900
Human immunization with a polymorphic malaria vaccine candidate induced antibodies to conserved epitopes that promote functional antibodies to multiple parasite strains.Q53698025
The complement system contributes to functional antibody-mediated responses induced by immunization with Plasmodium falciparum malaria sporozoites.Q55353878
Mouse strains with typical mammalian levels of complement activityQ69418249
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectmalariaQ12156
P304page(s)610
P577publication date2019-02-05
P1433published inNature CommunicationsQ573880
P1476titleTargets of complement-fixing antibodies in protective immunity against malaria in children
P478volume10

Reverse relations

cites work (P2860)
Q92965786Antibodies against Plasmodium falciparum malaria at the molecular level
Q99709750Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia
Q90107838Antibody-mediated complement activation in pathology and protection
Q90300290Complement in malaria immunity and vaccines
Q91918114Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives
Q91712984Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity
Q90450452IgM in human immunity to Plasmodium falciparum malaria
Q89559305Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial
Q92664225Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort
Q104077094Seasonal malaria chemoprevention: closing the know-do gap
Q110697512Serology for Plasmodium vivax surveillance: A novel approach to accelerate towards elimination
Q104617066Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection
Q89516787The Blood Stage Antigen RBP2-P1 of Plasmodium vivax Binds Reticulocytes and Is a Target of Naturally Acquired Immunity

Search more.